Previous clinical trials have demonstrated that the expression of immune checkpoints, such as PD-L1, in various patient populations can predict treatment efficacy, including pembrolizumab vs. chemotherapy, pembrolizumab vs. platinum-based chemotherapy for advanced NSCLC (26–28). Here, CD274 is linked to non-small cell lung carcinoma.